Cancer Drugs news from FierceBioResearcher

The argument over the FDA's role in regulating cancer therapies often comes down to one man: Dr. Richard Pazdur, a veteran oncologist and chief of the agency's oncology office. Patient groups and Read more...

In a study that may change the way that cancer drugs are developed and prescribed, a research group composed of Roche scientists and doctors at the prestigious Brigham and Women's Hospital in Boston Read more...

Oxford University's Leonard Seymour and a group of his colleagues are preparing to move a new approach to fighting cancer into human trials. They've been working on viruses that target cancer cells in the hope that the new approach could be used to replace chemotherapy, which has a host of harsh side effects. In order to make it work, the scientists had to create a polymer coat for the virus to shield it from destruction by the human immune system. That has allowed the virus, in animal …

Read more...

New research appearing in the Journal of Biology shows that even low doses of chemotherapy are killing brain cells and cancer drugs are more malignant to healthy cells than diseased cells. The study focused on the effects of cisplatin, cytarabine and carmustine on rats and found that healthy cells were still dying weeks after therapy. And the harsh therapy not only targeted the dividing cells that spread cancer, but normal cells that weren't dividing. The study at the University …

Read more...

Researchers at the University of Warwick are examining a way of using bacteria to manufacture a new suite of potential anti-cancer drugs that are difficult to create synthetically on a lab bench. The bacterium Streptomyces coelicolor naturally produce antibiotics called prodiginines. This group of antibiotics has stimulated much recent interest as they can be used to target and kill cancer cells. A synthetic prodiginine analogue called GX15-070 is currently in phase I and II cancer …

Read more...

With research into new cancer drugs booming, a recent study suggests that researchers may soon encounter a shortage of cancer patients for their clinical trials. The Geriatric Oncology Consortium counted 679 Phase I-III clinical trials planned in the U.S. for breast, lung and prostate cancer therapies. Those trials would need 238,000 cancer patients to participate, or 50 percent of everyone suffering from the diseases. Less than 10 percent of cancer patients are currently engaged in a …

Read more...